Magnesium Glycinate is Safe and May Be Beneficial for Patients with a History of Seizures
Magnesium glycinate is not only safe but potentially beneficial for patients with a seizure history, as magnesium supplementation has demonstrated anticonvulsant properties and may reduce seizure frequency in drug-resistant epilepsy. 1
Evidence Supporting Safety and Potential Benefit
The available evidence strongly suggests magnesium supplementation poses no contraindication for seizure patients and may actually provide therapeutic benefit:
Direct Clinical Evidence
A retrospective study of 22 patients with drug-resistant epilepsy showed significant seizure reduction with oral magnesium supplementation (primarily magnesium oxide). Seizure days per month decreased from 15.3 to 7.8 days at 6-12 months follow-up (p=0.004), with 36% of patients achieving ≥75% response rate and two patients becoming seizure-free 1. The most common side effect was diarrhea (4/22 patients), with most patients well-maintained on 420 mg twice daily 1.
Mechanistic Support
Magnesium functions as a CNS depressant and antagonizes excitation through the N-methyl-D-aspartate (NMDA) receptor, which is a key mechanism in seizure prevention 2. Studies demonstrate that:
- Low magnesium levels are associated with decreased seizure thresholds in both animal models and human studies 3, 2
- People with epilepsy often have lower serum magnesium levels than controls (1.80 vs. 2.02 mg/dL, p<0.001) 4
- Higher dietary magnesium intake (>350 mg/day) was associated with lower epilepsy risk (HR: 0.52) in a 22-year prospective study 5
Animal Studies Confirm Safety
Magnesium oxide supplementation in rats showed protective effects against maximal electroshock seizures and enhanced the activity of standard antiepileptic drugs like phenytoin and carbamazepine 6. When combined with ketogenic diet, magnesium supplementation did not interfere with antiseizure properties 7.
Practical Considerations
Magnesium glycinate specifically is an excellent choice because:
- It has better gastrointestinal tolerance than magnesium oxide
- The glycinate form has superior bioavailability
- The FDA labeling indicates no specific contraindications for seizure patients 8
Dosing Guidance
Based on the clinical evidence, typical therapeutic dosing ranges from 420-500 mg of elemental magnesium twice daily 1. Do not exceed recommended doses as indicated on product labeling 8.
Important Caveats
- The FDA labeling notes these products are supplements, not evaluated for treating specific diseases 8
- Magnesium supplementation should be adjunctive to, not replacement for, prescribed antiepileptic medications
- Monitor for diarrhea, the most common side effect
- Patients on established antiepileptic regimens should continue their medications—magnesium may enhance their effectiveness 6
Clinical Bottom Line
There is no contraindication to magnesium glycinate use in patients with seizure history. In fact, the evidence suggests potential benefit, particularly for those with drug-resistant epilepsy or suboptimal seizure control. The safety profile is favorable with minimal side effects, and the mechanistic rationale is sound given magnesium's role in neuronal excitability and NMDA receptor modulation 9.